New Drug Dostarlimab Achieves 100% Cure Rate in Rectal Cancer Trial

Phase II study shows complete tumor eradication in all patients with mismatch repair-deficient rectal cancer, offering a potential non-invasive treatment alternative.

• Dostarlimab demonstrated a 100% clinical complete response rate in 42 patients with advanced rectal cancer.
• Patients showed no signs of cancer recurrence after an average follow-up of 26.3 months.
• The treatment bypasses the need for chemotherapy, radiation, and surgery, significantly improving quality of life.
• Researchers plan further studies on other types of colorectal cancers to confirm these results.
• The findings were presented at the 2024 American Society of Clinical Oncology annual meeting.

3 Articles

New Atlas Healio BGR